EA201492271A1 - Соединения хроманов - Google Patents

Соединения хроманов

Info

Publication number
EA201492271A1
EA201492271A1 EA201492271A EA201492271A EA201492271A1 EA 201492271 A1 EA201492271 A1 EA 201492271A1 EA 201492271 A EA201492271 A EA 201492271A EA 201492271 A EA201492271 A EA 201492271A EA 201492271 A1 EA201492271 A1 EA 201492271A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
treatment
pharmaceutical composition
alzheimer
chroman
Prior art date
Application number
EA201492271A
Other languages
English (en)
Other versions
EA026380B1 (ru
Inventor
Ресуке Мунаката
Макото Иноуе
Хироаки Томинага
Синго Ямасаки
Ясухиро Сиина
Кийохиро Самидзу
Хисао Хамагути
Линь Хун
Original Assignee
Коментис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Коментис, Инк. filed Critical Коментис, Инк.
Publication of EA201492271A1 publication Critical patent/EA201492271A1/ru
Publication of EA026380B1 publication Critical patent/EA026380B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Изобретение относится к соединению, которое полезно в качестве активного ингредиента фармацевтической композиции, в частности фармацевтической композиции для профилактики или лечения состояний, связанных с и/или опосредованных активностью β-секретазы, гидролизом участка расщепления β-секретазы белка-предшественника амилоида и/или накоплением белка β-амилоида, включая фармацевтические композиции для профилактики или лечения, включая без ограничения глаукому, MCI (легкое когнитивное нарушение) или болезнь Альцгеймера, главным образом болезнь Альцгеймера.
EA201492271A 2012-05-30 2013-05-29 Соединения хроманов EA026380B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261653321P 2012-05-30 2012-05-30
US201361782038P 2013-03-14 2013-03-14
PCT/US2013/043016 WO2013181202A2 (en) 2012-05-30 2013-05-29 Chromane compounds

Publications (2)

Publication Number Publication Date
EA201492271A1 true EA201492271A1 (ru) 2015-10-30
EA026380B1 EA026380B1 (ru) 2017-04-28

Family

ID=49674034

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492271A EA026380B1 (ru) 2012-05-30 2013-05-29 Соединения хроманов

Country Status (15)

Country Link
US (2) US8975415B2 (ru)
EP (1) EP2854797A4 (ru)
JP (1) JP2015518048A (ru)
KR (1) KR20150023536A (ru)
CN (1) CN104394862A (ru)
AR (1) AR091203A1 (ru)
AU (1) AU2013267555A1 (ru)
BR (1) BR112014029597A2 (ru)
CA (1) CA2873678A1 (ru)
EA (1) EA026380B1 (ru)
HK (1) HK1208817A1 (ru)
MX (1) MX2014014066A (ru)
SG (1) SG11201407796YA (ru)
TW (1) TW201408672A (ru)
WO (1) WO2013181202A2 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181202A2 (en) 2012-05-30 2013-12-05 Astellas Pharma Inc. Chromane compounds
US10053453B2 (en) 2014-10-07 2018-08-21 Astrazeneca Ab Compounds and their use as BACE inhibitors
CN110790753B (zh) * 2019-11-18 2023-04-07 上海医药工业研究院 艾拉普林对甲苯磺酸盐、其制备方法和应用
CN110818694B (zh) * 2019-11-18 2023-04-21 上海医药工业研究院有限公司 艾拉普林中间体及其应用
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法
CN110713483B (zh) * 2019-11-18 2023-04-07 上海医药工业研究院 艾拉普林中间体及艾拉普林的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000663A2 (en) 1999-06-28 2001-01-04 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
US20040121947A1 (en) 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
JP4547152B2 (ja) 2001-10-23 2010-09-22 オクラホマ メディカル リサーチ ファウンデーション β−セクレターゼ阻害剤および使用方法
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
SI1699455T1 (sl) 2003-12-15 2013-10-30 Merck Sharp & Dohme Corp. Heterocikliäśni aspartil proteazni inhibitorji
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
WO2010013302A1 (ja) * 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
JP5444240B2 (ja) * 2008-07-28 2014-03-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
CA2731209A1 (en) * 2008-07-28 2010-02-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
WO2010021680A2 (en) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
JP5579720B2 (ja) * 2008-09-11 2014-08-27 アムジエン・インコーポレーテツド ベータ−セクレターゼ調節物質としてのスピロ四環式化合物および使用法
CA2753730C (en) 2009-03-13 2020-12-22 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US8461160B2 (en) 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
WO2011072064A1 (en) * 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
EP2539322B1 (en) * 2010-02-24 2014-01-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
JP5584352B2 (ja) * 2010-03-15 2014-09-03 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
US8883782B2 (en) * 2010-03-15 2014-11-11 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
US20120065195A1 (en) * 2010-03-31 2012-03-15 Clark Christopher T Compounds for treating neurodegenerative diseases
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2012040641A2 (en) 2010-09-24 2012-03-29 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
TW201300380A (zh) 2010-10-19 2013-01-01 Comentis Inc 抑制β－分泌酶活性之噁二唑化合物及其使用方法
TW201307357A (zh) 2010-11-22 2013-02-16 Array Biopharma Inc 治療神經退化性疾病之化合物
WO2012071279A1 (en) 2010-11-23 2012-05-31 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
EP2673279A1 (en) 2011-02-07 2013-12-18 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
US9079919B2 (en) 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
US9296759B2 (en) 2011-09-21 2016-03-29 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9650336B2 (en) 2011-10-10 2017-05-16 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
WO2013181202A2 (en) 2012-05-30 2013-12-05 Astellas Pharma Inc. Chromane compounds
EP2669286A1 (en) 2012-05-31 2013-12-04 Ares Trading S.A. Spiro tetrahydro-benzothiophen derivatives useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
US20140179695A1 (en) 2014-06-26
WO2013181202A2 (en) 2013-12-05
HK1208817A1 (en) 2016-03-18
EP2854797A2 (en) 2015-04-08
MX2014014066A (es) 2015-03-19
AR091203A1 (es) 2015-01-21
CA2873678A1 (en) 2013-12-05
KR20150023536A (ko) 2015-03-05
BR112014029597A2 (pt) 2017-11-07
SG11201407796YA (en) 2014-12-30
EP2854797A4 (en) 2016-01-13
CN104394862A (zh) 2015-03-04
US9242973B2 (en) 2016-01-26
TW201408672A (zh) 2014-03-01
AU2013267555A1 (en) 2014-12-04
EA026380B1 (ru) 2017-04-28
WO2013181202A3 (en) 2014-01-30
US20150225386A1 (en) 2015-08-13
JP2015518048A (ja) 2015-06-25
US8975415B2 (en) 2015-03-10

Similar Documents

Publication Publication Date Title
EA201492271A1 (ru) Соединения хроманов
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201270824A1 (ru) Соединения для уменьшения продукции бета-амилоида
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201892339A3 (ru) Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201270225A1 (ru) СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201590353A1 (ru) Способы лечения болезни альцгеймера и фармацевтические композиции
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201391561A1 (ru) Новые соединения-модуляторы gpr-119
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
EA201101479A1 (ru) Новые p2x7r антагонисты и их применение
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU